LISATA THERAPEUTICS, INC. (LSTA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1280583022
LISATA THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 170,000.00 USD |
| Operating income | -18.21 m USD |
| EBIT | -17.55 m USD |
| Net income | -16.59 m USD |
| Diluted EPS – continuing operations | -1.91 USD |
Full history since 1990, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About LISATA THERAPEUTICS, INC.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
More stocks
- INTRUSION INC (INTZ)
- PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH)
- EWSB Bancorp, Inc. /MD/ (EWSB)
- Gyrodyne, LLC (GYRO)
- Granite Point Mortgage Trust Inc. (GPMT)
- Vyome Holdings, Inc (HIND)
- PAVmed Inc. (PAVM)
- Mobiquity Technologies, Inc. (MOBQ)
- MedApp S.A (MDA.WA)
- Rise Gold Corp. (RYES)
- Foxx Development Holdings Inc. (FOXX)
- Next Meats Holdings, Inc. (NXMH)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.